Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW.

Mayo Clin Proc. 2006 Jul;81(7):925-34.

PMID:
16835972
2.

Serum urate levels and gout flares: analysis from managed care data.

Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.

J Clin Rheumatol. 2006 Apr;12(2):61-5.

PMID:
16601538
3.

Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.

Curr Med Res Opin. 2009 Jul;25(7):1711-9. doi: 10.1185/03007990903017966.

PMID:
19485724
4.

Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.

Primatesta P, Plana E, Rothenbacher D.

BMC Musculoskelet Disord. 2011 May 20;12:103. doi: 10.1186/1471-2474-12-103.

5.

Opportunities for improving medication use and monitoring in gout.

Singh JA, Hodges JS, Asch SM.

Ann Rheum Dis. 2009 Aug;68(8):1265-70. doi: 10.1136/ard.2008.092619. Epub 2008 Aug 13.

PMID:
18701554
6.

Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG.

Rheumatology (Oxford). 2005 Aug;44(8):1038-42. Epub 2005 May 3.

PMID:
15870145
7.

Adherence and persistence to urate-lowering therapies in the Irish setting.

McGowan B, Bennett K, Silke C, Whelan B.

Clin Rheumatol. 2016 Mar;35(3):715-21. doi: 10.1007/s10067-014-2823-8. Epub 2014 Nov 20.

PMID:
25409858
8.

Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.

Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G.

Rheumatology (Oxford). 2013 Jun;52(6):1126-31. doi: 10.1093/rheumatology/kes431. Epub 2013 Feb 7.

PMID:
23392592
9.

Chronic kidney disease in gout in a managed care setting.

Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E.

BMC Nephrol. 2011 Aug 3;12:36. doi: 10.1186/1471-2369-12-36.

10.

[Quality of treatment in gouty patients considering EULAR recommendations].

Radak-Perović M, Zlatković-Svenda M.

Srp Arh Celok Lek. 2012 Nov-Dec;140(11-12):717-21. Serbian.

11.

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.

Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M.

J Rheumatol. 2004 Aug;31(8):1575-81.

PMID:
15290738
12.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
13.

Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.

Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.

14.

Quality of care for gout in the US needs improvement.

Singh JA, Hodges JS, Toscano JP, Asch SM.

Arthritis Rheum. 2007 Jun 15;57(5):822-9.

15.

Colchicine prescribing and safety monitoring in patients with gout.

Ly J, Gow P, Dalbeth N.

N Z Med J. 2007 Nov 9;120(1265):U2808.

PMID:
18264188
16.

Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC.

Rheumatol Int. 2015 Nov;35(11):1799-807. doi: 10.1007/s00296-015-3284-3. Epub 2015 May 20.

17.

Utilization of allopurinol in the Australian community.

Chung Y, Lu CY, Graham GG, Mant A, Day RO.

Intern Med J. 2008 Jun;38(6):388-95. doi: 10.1111/j.1445-5994.2008.01641.x. Epub 2008 Apr 14.

PMID:
18422564
18.

Factors associated with recurrent hospital admissions for gout: a case-control study.

Hutton I, Gamble G, Gow P, Dalbeth N.

J Clin Rheumatol. 2009 Sep;15(6):271-4. doi: 10.1097/RHU.0b013e3181b562f8.

PMID:
19734730
19.

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N.

Arthritis Rheum. 2012 Aug;64(8):2529-36. doi: 10.1002/art.34488.

20.

Supplemental Content

Support Center